ABBV
$104.64
Abbvie
($.25)
(.24%)
ABBV
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $2.85
Revenue:  $13.75 Bil
Friday
Jan 29
7:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Friday, October 30, 2020

What do you expect when ABBV reports earnings?
Beat
Meet
Miss

Where is ABBV's stock price going from here?
Up
Flat
Down
Stock chart of ABBV
Analysts
Summary of analysts' recommendations for ABBV
Score
Grade
Pivots
Resistance
$107.21
$106.31
$105.45

$104.55

Support
$103.68
$102.78
$101.91
Tweet
Growth
Description
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly